Eastern International Ltd. - Ordinary Shares (ELOG)
Live price chart, market sentiment, and community perspectives for Eastern International Ltd. (NASDAQ: ELOG).
Live price chart, market sentiment, and community perspectives for Eastern International Ltd. (NASDAQ: ELOG).
On our fundamental desk, looking at the Form 20-F for fiscal year 2026, Eastern International's top-line revenue grew to $45.6M from $40.0M, but gross profit dropped to $4.2M. Higher selling and GandA expenses of $5.3M completely crushed operating margins, dragging them into a loss of $(1.06M) and a net loss of $(1.15M). We have to weigh this top-line expansion against deteriorating bottom-line execution.
Watching the valuation models at CirclFi, ELOG sits firmly in the bottom tier with a quality score of 2.0 out of 10. With zero out of zero models projecting upside at the current sub-dollar valuation, the market is treating the equity with high skepticism, labeling it a potential value trap given the structural shift from a prior net income of $1.78M down to a negative EPS of $(0.10).
From a corporate governance standpoint, the August 2026 6-K filings show some notable shifts. Following the resignation of two board directors in early August, the company quickly appointed K. Brice 'Rick' Toussaint and Bin Zhou as new independent directors to chair the audit and compensation committees. Markets will be closely watching if this new leadership can address the surging SGandA overhead.
As a portfolio manager reviewing micro-cap logistics exposure, ELOG's market cap around $9.97M to $11.8M and a share price hovering between $0.76 and $0.93 make it a very speculative play. Total assets sit at $32.28M with shareholders' equity at $15.19M, backed by $3.05M in cash against $5.04M in current bank and other borrowings. The balance sheet requires careful ongoing monitoring.
Analyzing the geographic and operational structure, the Cayman Islands holding company operates entirely through PRC-based subsidiaries delivering freight and cargo logistics in China. Investors must factor in cross-border reporting structures, local regulatory exposure, and the operational risks typical of US-listed Chinese micro-caps when running valuation scenarios.
Explore plasma cleansing, somatic organ swaps, and BCI.